Dr. Amar R. Deshpande, MD

Dr. Deshpande practices at Sylvester Comprehensive Cancer Center in Miami, Florida, part of University of Miami.

Dr. Deshpande's NPI, 1710189915, was assigned on June 1, 2007. Dr. Deshpande graduated from University of Miami, Miller School of Medicine in 2002. Dr. Deshpande holds Florida license ME101411.

Dr. Deshpande's primary practice is Sylvester Comprehensive Cancer Center, at 1475 Nw 12th Ave, Miami, FL 33136.

Dr. Deshpande's primary practice is Sylvester Comprehensive Cancer Center in Miami, Florida, part of University of Miami. Dr. Deshpande is also affiliated with Jackson Memorial Hospital. The medical group on file is University of Miami Health System.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Deshpande practices, 2 sites in all. Vendor and product names are available with a free account.

Gastroenterology is Dr. Deshpande's primary specialty in the NPI Registry, under taxonomy code 207RG0100X. Dr. Deshpande is board certified in gastroenterology by the American Board of Internal Medicine. Dr. Deshpande is licensed in Florida.

Dmand AI lists chronic inflammatory bowel disease (IBD), colonoscopy and upper GI endoscopy among the conditions Dr. Deshpande treats.

CMS data shows 121 Medicare services from Dr. Deshpande across 5 procedure codes in 2024, for 94 Medicare patients. Medicare paid $8,970 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 94 Medicare patients who saw Dr. Deshpande in 2024. The largest group is 75 to 84, with 32 patients. 75% of them have high cholesterol, and 74% have high blood pressure. 47% are also on Medicaid. Their average risk score is 3.32, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Deshpande's median patient age at 57, with 45% women.

In 2024, Dr. Deshpande wrote 178 Medicare Part D claims for 44 patients. 62% of them were for generic drugs. CMS names the drug for 35 of them, across 2 drugs with 11 or more claims each, at $512,815 in total drug cost. In 2023, CMS named 25 claims across 2 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Deshpande for performance year 2024, reported as part of a group. Dr. Deshpande accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Deshpande as offering telehealth. CMS counts 32 procedures of colonoscopy by Dr. Deshpande, more than 55% of the clinicians it reports for that procedure.

Dmand AI links 81 papers to Dr. Deshpande, published from 2006 to 2025. 2024 was the busiest year, with 7. The most frequent topics are Crohn Disease, Colitis, Ulcerative and Inflammatory Bowel Diseases. Dr. Deshpande has published most often in Aliment Pharmacol Ther. Dr. Deshpande's most frequent co-authors are Maria Teresa Abreu, MD, Oriana Mazorra Damas, MD and David H. Kerman, MD.

Dmand AI links Dr. Deshpande to 1 clinical trial. Conditions studied include Crohn Disease and Inflammatory Bowel Diseases.

CMS Open Payments shows 14 general payments to Dr. Deshpande from 4 drug and device companies from 2016 to 2022. Consulting fees make up the largest share, 75% of the total. Takeda Pharmaceuticals U.S.A., Inc. paid the most, $9,274.

Dr. Deshpande graduated from University of Miami, Miller School of Medicine in 2002.